Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02706899

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This is a phase 1/2 study to evaluate the combination of vadastuximab talirine (SGN-CD33A; 33A) and azacitidine in subjects with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or high risk myelodysplastic syndrome (MDS).

Status: 
Recruiting
Study Date: 
Mon, 02/01/2016 to Wed, 05/01/2019
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: vadastuximab talirine Other Names: 33A SGN-CD33A Drug: Azacitidine azacitidine 75 mg/m2 given intravenously or subcutaneously x 7 days every 4 weeks Drug: Placebo (for 33A) Placebo supplied in single-use vials matching 33A